Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.40 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.40 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4540956 | 0.85 | CA1 (0.60) | CA1CA2CA7CA9CA12 | |
| SCHEMBL4760417 | 0.82 | CA1 (0.50) | CA1CA2CA7CA9CA12 | |
| Hydrochloric Acid SCHEMBL28200109 | 0.80 | CA1 (0.48) | CA1CA2CA7CA9CA12 | |
| SCHEMBL1020975 | 0.80 | CA1 (0.42) | CA1CA2CA7CA9CA12 | |
| SCHEMBL15541407 | 0.79 | CA1 (0.52) | CA1CA2CA7CA9CA12 | |
| SCHEMBL17485907 | 0.78 | CA1 (0.57) | CA1CA2CA7CA9CA12 | |
| SCHEMBL2539698 | 0.78 | CA1 (0.57) | CA1CA2CA7CA9CA12 | |
| SCHEMBL4669496 | 0.77 | CA1 (0.50) | CA1CA2CA7CA9CA12 | |
| SCHEMBL20386672 | 0.77 | CA1 (0.50) | CA1CA2CA7CA9CA12 | |
| SCHEMBL29449742 | 0.77 | CA1 (0.50) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108863920-A | Pesticidal compound | 先正达参股股份有限公司 | 2018-11-23 | — | — | CN | disclosed |
| CN-105849084-B | Insecticidal compounds | 先正达参股股份有限公司 | 2018-07-20 | — | — | CN | disclosed |
| CN-105849084-A | Insecticidal compounds | 先正达参股股份有限公司 | 2016-08-10 | — | — | CN | disclosed |
| CN-105384739-A | Pyrazolo[3,4-c]pyridine derivative | CSPC ZHONGQI PHARMACEUTICAL TECH (SHIJIAZHUANG) CO LTD | 2016-03-09 | — | — | CN | disclosed |
| CN-101878217-B | Agent for prevention and/or treatment of skin diseases | KYOWA HAKKO KIRIN CO LTD | 2014-01-15 | — | — | CN | disclosed |
| CN-103328454-A | 1,4 oxazines as BACE1 and/or BACE2 inhibitors | HOFFMANN LA ROCHE | 2013-09-25 | — | — | CN | disclosed |
| CN-101878217-A | Agent for prevention and/or treatment of skin diseases | KYOWA HAKKO KIRIN CO LTD | 2010-11-03 | — | — | CN | disclosed |
| EP-1463506-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| US-20090215770-A1 | Substituted Quinazoline Derivatives as Inhibitors of Aurora Kinases | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
| US-7402585-B2 | Substituted quinazoline derivatives as inhibitors of aurora kinases | ASTRAZENECA AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-20050070561-A1 | Substituted quinazoline derivatives as inhibitors of aurora kinases | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | US | disclosed |
| EP-1463506-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | Astrazeneca AB (SE) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003055491-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | ASTRAZENECA AB (SE) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070561-A1 | Substituted quinazoline derivatives as inhibitors of aurora kinases | AURKC, AURKA, AURKB | CA1 4287/4885CA2 1491/4885CA7 1961/4885 |
| US-20090215770-A1 | Substituted Quinazoline Derivatives as Inhibitors of Aurora Kinases | AURKC, AURKA, AURKB | CA1 4300/4885CA2 2163/4885CA7 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.